

1
2
3
4
5
6
7
8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7484

13 **COASTAL DRUGS, LLC, DBA COASTAL**
14 **DRUGS**

15 **HEMA M. PATEL, CEO**
16 **ALPESH M. PATEL, PRESIDENT**
17 **3500 E. Broadway**
18 **Long Beach, CA 90803**

DEFAULT DECISION AND ORDER AS
TO COASTAL DRUGS, LLC

19 **Pharmacy Permit No. PHY 55429,**

[Gov. Code, §11520]

20 **and**

21 **CATHERINE ADHIAMBO MWANGALE**
22 **2365 Promontory Dr.**
23 **Signal Hill, CA 90755**

24 **Registered Pharmacist License No. RPH**
25 **44540**

26 Respondents.

27 **FINDINGS OF FACT**

28 1. On or about September 7, 2023, Complainant Anne Sodergren, in her official capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs, filed Accusation No. 7484 against Coastal Drugs, LLC, dba Coastal Drugs (Coastal Drugs), and Catherine Mwangale, before the Board of Pharmacy. (Accusation attached as Exhibit A.)

2. On or about June 12, 2020, the Board of Pharmacy (Board) issued Pharmacy Permit No. PHY 55429 to Coastal Drugs. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought in Accusation No. 7484 and will expire on January 1, 2024, unless renewed.

3. On or about September 14, 2023, Respondent Coastal Drugs was served by Certified and First Class Mail copies of the Accusation No. 7484, Statement to Respondent, Notice of Defense, Request for Discovery, and Discovery Statutes (Government Code sections 11507.5, 11507.6, and 11507.7) at Respondent Coastal Drugs' address of record which, pursuant to Business and Professions Code section 4100, is required to be reported and maintained with the Board. Respondent Coastal Drugs' address of record was and is: 3500 E. Broadway, Long Beach, CA 90803.

4. Service of the Accusation was effective as a matter of law under the provisions of Government Code section 11505(c) and/or Business and Professions Code section 124.

5. Government Code section 11506(c) states, in pertinent part:

(c) The respondent shall be entitled to a hearing on the merits if the respondent files a notice of defense . . . and the notice shall be deemed a specific denial of all parts of the accusation . . . not expressly admitted. Failure to file a notice of defense . . . shall constitute a waiver of respondent's right to a hearing, but the agency in its discretion may nevertheless grant a hearing.

6. The Board takes official notice of its records and the fact that Respondent Coastal Drugs failed to file a Notice of Defense within 15 days after service upon them of the Accusation, and therefore waived their right to a hearing on the merits of Accusation No. 7484.

7. California Government Code section 11520(a) states, in pertinent part:

(a) If the respondent either fails to file a notice of defense . . . or to appear at the hearing, the agency may take action based upon the respondent's express admissions or upon other evidence and affidavits may be used as evidence without any notice to respondent

8. Pursuant to its authority under Government Code section 11520, the Board finds that Respondent Coastal Drugs is in default. The Board will take action without further hearing and, based on the relevant evidence contained in the Default Decision Investigatory Evidence Packet in this matter, finds that the charges and allegations in Accusation No. 7484, are separately and

severally, found to be true and correct by clear and convincing evidence.

9. The Board finds that the actual costs for Investigation and Enforcement are \$6,636.25 as of October 20, 2023.

DETERMINATION OF ISSUES

1. Based on the foregoing findings of fact, Respondent Coastal Drugs, LLC, dba Coastal Drugs, has subjected its Pharmacy Permit No. PHY 55429 to discipline.

2. The agency has jurisdiction to adjudicate this case by default.

3. The Board of Pharmacy is authorized to revoke Pharmacy Permit No. PHY 55429 based upon the following violations alleged in the Accusation which are supported by the evidence contained in the Default Decision Investigatory Evidence Packet in this case:

a. Business and Professions Code section 4301, subdivision (f), acts involving moral turpitude, dishonesty, fraud, deceit, or corruption;

b. Business and Professions Code section 4301, subdivisions (j) and/or (o), failure to maintain current inventory and records; and

c. Business and Professions Code section 4301, unprofessional conduct.

\\

\\

\\

\\

\\

\\

\\

\\

\\

\\

\\

\\

\\

ORDER

IT IS SO ORDERED that Pharmacy Permit No. PHY 55429, issued to Respondent Coastal Drugs, LLC, dba Coastal Drugs, is revoked.

IT IS FURTHER ORDERED that Coastal Drugs, LLC is prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee until Pharmacy Permit No. PHY 55249 is reinstated.

Pursuant to Government Code section 11520, subdivision (c), Respondent may serve a written motion requesting that the Decision be vacated and stating the grounds relied on within seven (7) days after service of the Decision on Respondent. The agency in its discretion may vacate the Decision and grant a hearing on a showing of good cause, as defined in the statute.

This Decision shall become effective at 5:00 p.m. on January 17, 2024.

It is so ORDERED on December 18, 2023.

BOARD OF PHARMACY DEPARTMENT
OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By



Seung W. Oh, Pharm. D.
Board President

66323571.DOCX
DOJ Matter ID:LA2023601260

Attachment:
Exhibit A: Accusation

Exhibit A

Accusation

1 ROB BONTA
Attorney General of California
2 SHAWN P. COOK
Supervising Deputy Attorney General
3 MATTHEW S. BEASLEY
Deputy Attorney General
4 State Bar No. 288070
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6705
6 Facsimile: (916) 731-2126
E-mail: Matthew.Beasley@doj.ca.gov
7 *Attorneys for Complainant*

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7484

13 **COASTAL DRUGS, LLC, DBA COASTAL**
14 **DRUGS**
15 **HEMA M. PATEL, CEO**
16 **ALPESH M. PATEL, PRESIDENT**
3500 E. Broadway
Long Beach, CA 90803

ACCUSATION

17 **Pharmacy Permit No. PHY 55429,**

18 **and**

19 **CATHERINE ADHIAMBO MWANGALE**
20 **2365 Promontory Dr.**
Signal Hill, CA 90755

21 **Registered Pharmacist License No.**
22 **RPH 44540**

23 Respondents.

24
25
26 **PARTIES**

27 1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
28 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

2. On or about January 25, 2017, the Board of Pharmacy issued Pharmacy Permit Number PHY 55429 to Benzer Pharmacy Holding LLC, dba Benzer CA1 LLC. On or about June 12, 2020, Benzer Pharmacy Holding LLC changed its name to do business as Coastal Drugs, LLC, dba Coastal Drugs (Respondent Coastal). Hema M. Patel has served or been listed in Board records as Chief Executive Officer of Respondent Coastal. Alpesh M. Patel has served or been listed in Board records as President of Respondent Coastal. Pharmacy Permit Number PHY 55429 was in full force and effect at all times relevant to the charges brought herein and will expire on January 1, 2024, unless renewed.

3. On or about August 13, 1991, the Board of Pharmacy issued Pharmacist License Number RPH 44540 to Catherine Adhiambo Mwangale (Respondent Mwangale). Pharmacist License Number RPH 44540 was in full force and effect at all times relevant to the charges brought herein and will expire on January 31, 2025, unless renewed. Respondent Mwangale was the Pharmacist-In-Charge of Respondent Coastal from May 28, 2021 to March 4, 2022.

JURISDICTION

4. This Accusation is brought before the Board of Pharmacy (Board), under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.

5. Code section 4011 provides that the Board shall administer and enforce both the Pharmacy Law (Bus. & Prof. Code, § 4000 *et seq.*) and the Uniform Controlled Substances Act (Health & Safety Code, § 11000 *et seq.*).

6. Code section 4300, subdivision (a), provides that every license issued by the Board may be suspended or revoked.

7. Section 4300.1 of the Code states:

The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

1 8. Section 4302 of the Code states:

2 The board may deny, suspend, or revoke any license where conditions exist in
3 relation to any person holding 10 percent or more of the ownership interest or where
4 conditions exist in relation to any officer, director, or other person with management or
 control of the license that would constitute grounds for disciplinary action against a
 licensee.

5 **STATUTORY AND REGULATORY PROVISIONS**

6 9. Section 4022 of the Code states:

7 Dangerous drug or dangerous device means any drug or device unsafe for
8 self-use in humans or animals, and includes the following:

9 (a) Any drug that bears the legend: Caution: federal law prohibits dispensing
 without prescription, Rx only, or words of similar import.

10 (b) Any device that bears the statement: Caution: federal law restricts this
11 device to sale by or on the order of a _____, Rx only, or words of similar
 import, the blank to be filled in with the designation of the practitioner licensed to use
 or order use of the device.

12 (c) Any other drug or device that by federal or state law can be lawfully
13 dispensed only on prescription or furnished pursuant to Section 4006.

14 10. Section 4081 of the Code states, in pertinent part:

15 (a) All records of manufacture and of sale, acquisition, or disposition of
16 dangerous drugs or dangerous devices shall be at all times during business hours open
17 to inspection by authorized officers of the law, and shall be preserved for at least
18 three years from the date of making. A current inventory shall be kept by every
19 manufacturer, wholesaler, pharmacy, veterinary food-animal drug retailer, physician,
20 dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or
 establishment holding a currently valid and unrevoked certificate, license, permit,
 registration, or exemption under Division 2 (commencing with Section 1200) of the
 Health and Safety Code or under Part 4 (commencing with Section 16000) of
 Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous
 drugs or dangerous devices.

21 (b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary
22 food-animal drug retailer shall be jointly responsible, with the pharmacist-in-charge
23 or representative-in-charge, for maintaining the records and inventory described in
 this section....

24 11. Section 4105 of the Code states, in pertinent part:

25 (a) All records or other documentation of the acquisition and disposition of
26 dangerous drugs and dangerous devices by any entity licensed by the board shall be
 retained on the licensed premises in a readily retrievable form.

27 ...

28 (c) The records required by this section shall be retained on the licensed
 premises for a period of three years from the date of making....

1 12. Code section 4113, subdivision (c), states: “The pharmacist-in-charge shall be
2 responsible for a pharmacy’s compliance with all state and federal laws and regulations pertaining to
3 the practice of pharmacy.”

4 13. Section 4301 of the Code states, in pertinent part:

5 The board shall take action against any holder of a license who is guilty of
6 unprofessional conduct or whose license has been issued by mistake. Unprofessional
conduct shall include, but is not limited to, any of the following:

7 ...

8 (f) The commission of any act involving moral turpitude, dishonesty, fraud,
9 deceit, or corruption, whether the act is committed in the course of relations as a
licensee or otherwise, and whether the act is a felony or misdemeanor or not.

10 ...

11 (j) The violation of any of the statutes of this state, of any other state, or of the
12 United States regulating controlled substances and dangerous drugs.

13 ...

14 (o) Violating or attempting to violate, directly or indirectly, or assisting in or
15 abetting the violation of or conspiring to violate any provision or term of this chapter
16 or of the applicable federal and state laws and regulations governing pharmacy,
including regulations established by the board or by any other state or federal
regulatory agency.

17 ...

18 14. Section 4306.5 of the Code states:

19 Unprofessional conduct for a pharmacist may include any of the following:

20 (a) Acts or omissions that involve, in whole or in part, the inappropriate
21 exercise of his or her education, training, or experience as a pharmacist, whether or
22 not the act or omission arises in the course of the practice of pharmacy or the
ownership, management, administration, or operation of a pharmacy or other entity
licensed by the board.

23 (b) Acts or omissions that involve, in whole or in part, the failure to exercise or
24 implement his or her best professional judgment or corresponding responsibility with
25 regard to the dispensing or furnishing of controlled substances, dangerous drugs, or
dangerous devices, or with regard to the provision of services.

26 (c) Acts or omissions that involve, in whole or in part, the failure to consult
27 appropriate patient, prescription, and other records pertaining to the performance of
28 any pharmacy function.

(d) Acts or omissions that involve, in whole or in part, the failure to fully maintain and retain appropriate patient-specific information pertaining to the performance of any pharmacy function.

15. Code section 4307, subdivision (a), states:

Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner member, officer, director, associate, or partner of any partnership, corporation, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manger, administrator, owner, member, officer, director, associate, or partner had knowledge or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manger, administrator, owner, member, officer, director, associate, or partner of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

16. California Code of Regulations, title 16, section 1718, states:

“Current Inventory” as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request for at least 3 years after the date of the inventory.

COST RECOVERY

17. Section 125.3 of the Code states, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

DRUG DESCRIPTIONS

18. *Hydroxychloroquine*, trade name Plaquenil, is a dangerous drug within the meaning of Code section 4022. Hydroxychloroquine is approved by the Food and Drug Administration (FDA) for the prevention and treatment of malaria, rheumatoid arthritis (RA) and system lupus

1 erythematosis. Frequent dosing can cause retinopathy and cardiac arrhythmias. Fatal overdoses
2 have been reported.

3 19. *Ivermectin*, trade name Stromectol, is a dangerous drug within the meaning of Code
4 section 4022. Ivermectin is approved by the FDA for the treatment of internal and external
5 parasitic infections including roundworm, hookworm, and scabies. Excessive use of the drug can
6 cause severe side effects including nausea, vomiting, diarrhea, blurred vision, dizziness, low blood
7 pressure, fast heart rate, mental status changes such as confusion, loss of balance, and seizures.

8 **FACTUAL ALLEGATIONS**

9 20. On or about March 28, 2020, the FDA approved an emergency use authorization
10 (EUA) to facilitate the availability of hydroxychloroquine for the treatment of COVID-19 to
11 certain hospitalized patients. On or about April 1, 2020, the Board issued a written statement
12 alerting pharmacists that hydroxychloroquine was to be used for certain hospitalized patients
13 only, based on the FDA's EUA, and recommended that pharmacists use their professional
14 judgment when dispensing drugs for the treatment or prevention of COVID-19. On June 15,
15 2020, the FDA revoked its EUA because the drug was found ineffective for the treatment or
16 prevention of COVID-19 and because of an increase in reports of serious cardiac adverse events.
17 On or about July 8, 2021, the National Institute of Health's (NIH) COVID-19 Treatment
18 Guidelines Panel recommended against the use of hydroxychloroquine and for the treatment of
19 COVID-19 in hospitalized and non-hospitalized patients.

20 21. In April 2020, the FDA issued a warning that ivermectin should not be used to treat
21 COVID-19 in humans. On or about February 11, 2021, the NIH panel released a statement that
22 there was insufficient evidence for the use of ivermectin in the treatment of COVID-19 and
23 recommended against its use for the prevention and treatment of COVID-19. On or about August
24 26, 2021, the Centers for Disease Control reiterated the FDA's caution about the potential risks of
25 using ivermectin for the prevention or treatment of COVID-19.

26 22. Respondent Coastal is located in Los Angeles County, California. Respondent
27 Coastal fills prescriptions for Ravkoo, an online pharmacy formerly known as Bonsa, in
28 California and receives compensation from patients for whom the prescriptions are filled.

1 23. In or around November 2021, Board enforcement staff received information
2 indicating that Respondent Coastal had affiliated with a network of pharmacies that were
3 dispensing hydroxychloroquine and ivermectin for the prevention and treatment of COVID-19.

4 24. On or about March 3, 2022, a Board investigator contacted Respondent Mwangale.
5 Respondent Mwangale stated that Coastal had received some electronic prescriptions from
6 Ravkoo, but none for hydroxychloroquine or ivermectin. Respondent Mwangale also stated that
7 Respondent Coastal filled a few prescriptions for hydroxychloroquine but not many.

8 25. On or about March 17, 2022, Respondent Coastal provided the Board investigator
9 with documents related to Respondent's prescriptions for hydroxychloroquine or ivermectin.
10 These documents showed that Respondent Coastal had dispensed 3 prescriptions for
11 hydroxychloroquine in 2019, 9 in 2020, 1,373 in 2021, and 1 in 2022. The documents further
12 showed that Respondent Coastal had dispensed 4 prescriptions for ivermectin in 2019, 0 in 2020,
13 1,075 in 2021, and 3 in 2022.

14 26. The Board investigator conducted an audit and found that, between January 1, 2019
15 and March 2, 2022, Respondent Coastal had purchased 29,300 tabs of hydroxychloroquine
16 200mg from wholesalers. The audit revealed that Respondent Coastal had an overage of 1,874
17 tabs of hydroxychloroquine 200mg. An overage indicates that Respondent Coastal sold more
18 tabs than it purchased, which is an indicator of fraud, and Respondents were unable to account for
19 this discrepancy.

20 27. The Board's audit further revealed that, between January 1, 2019 and March 2, 2022,
21 Respondent Coastal had purchased 30,020 tabs of ivermectin 3mg from wholesalers. The audit
22 revealed that Respondent Coastal had an overage of 3,203 tabs of ivermectin 3mg. Respondents
23 were unable to account for this discrepancy.

24 28. Further investigation by the Board revealed that Respondent Mwangale, as
25 Respondent Coastal's Pharmacist-In-Charge, verified and filled the bulk of the subject
26 prescriptions for hydroxychloroquine and ivermectin, and that many of these prescriptions came
27 from Ravkoo.

1 **FIRST CAUSE FOR DISCIPLINE**

2 (Acts Involving Moral Turpitude, Dishonesty, Fraud, Deceit, or Corruption)

3 29. Paragraphs 20 through 28 are incorporated by this reference.

4 30. Respondents are subject to disciplinary action under Code section 4301, subdivision
5 (f), in that they committed acts involving moral turpitude, dishonesty, fraud, deceit, or corruption,
6 in that Respondents accepted financial compensation for and dispensed hydroxychloroquine and
7 ivermectin, which are dangerous drugs, to patients for the treatment or prevention of COVID-19
8 despite recommendations from the Board, the FDA, and the NIH against doing so.

9 **SECOND CAUSE FOR DISCIPLINE**

10 (Failure to Maintain Current Inventory and Records)

11 31. Paragraphs 20 through 28 are incorporated by this reference.

12 32. Respondents are subject to disciplinary action under Code sections 4301, subdivisions
13 (j) and/or (o), for violating Code section 4081, subdivision (1), and 4105, subdivisions (a) and (c),
14 and California Code of Regulations, title 16, section 1718, in that Respondents failed to maintain
15 a current inventory for certain drugs and had insufficient records to explain discrepancies.

16 **THIRD CAUSE FOR DISCIPLINE**

17 (Failure to Exercise or Implement Best Professional Judgment or Corresponding Responsibility)

18 33. Paragraphs 20 through 28 are incorporated by this reference.

19 34. Respondent Mwangale is subject to disciplinary action under Code section 4301,
20 subdivisions (j) and/or (o), for violating Code section 4306.5, subdivisions (a), (b), and (c), in that
21 she failed to exercise or implement her best professional judgment and/or corresponding
22 responsibility by dispensing hydroxychloroquine and/or ivermectin for the prevention or
23 treatment of COVID-19, despite recommendations from the Board, the FDA, and the NIH against
24 doing so.

25 **FOURTH CAUSE FOR DISCIPLINE**

26 (Unprofessional Conduct)

27 35. Paragraphs 20 through 34 are incorporated by this reference.

28 36. Respondents are subject to disciplinary action under Code section 4301, for

unprofessional conduct in that they engaged in the activities described in Paragraphs 20 through 34 above.

OTHER MATTERS

37. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55429 issued to Respondent Coastal, Respondent Coastal shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit number PHY 55429 is placed on probation or until Pharmacy Permit Number PHY 55429 is reinstated if revoked.

38. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55429 issued to Respondent Coastal, while Hema M. Patel has been an officer and had knowledge of or knowingly participated in any conduct for which the license was disciplined, Hema M. Patel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until Pharmacy Permit Number PHY 55429 is reinstated if it is revoked.

39. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55429 issued to Respondent Coastal, while Alpesh M. Patel has been an officer and had knowledge of or knowingly participated in any conduct for which the license was disciplined, Alpesh M. Patel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until Pharmacy Permit Number PHY 55429 is reinstated if it is revoked.

40. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55429 issued to Respondent Coastal, while Respondent Mwangale has been the Pharmacist-In-Charge and had knowledge of or knowingly participated in any conduct for which the license was disciplined, Respondent Mwangale shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until Pharmacy Permit Number PHY 55429 is reinstated if it is revoked.

41. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License Number RPH 44540 issued to Respondent Mwangale, Respondent Mwangale shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 44540 is placed on probation or until Pharmacist License Number RPH 44540 is reinstated if it revoked.

DISCIPLINE CONSIDERATIONS

42. To determine the degree of discipline, if any, to be imposed on Respondents, Complainant alleges as follows:

a. On or about June 22, 2018, the Board issued Citation Number CI 2017 75922 based on violations of Code section 4301, subdivision (o), in conjunction with Code section 4314 and California Code of Regulations, title 16, section 1775, (variation from prescription). Citation Number CI 2017 75922 has been completed.

b. On or about July 28, 2020, the Board issued Citation Number CI 2018 81906 based on violations of Code section 4115, subdivision (e), (allowing unlicensed person to act as pharmacy technician). Citation Number CI 2018 81906 has been completed.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Pharmacy Permit Number PHY 55429, issued to Coastal Drugs, LLC, dba Coastal Drugs;

2. Revoking or suspending Pharmacist License Number RPH 44540, issued to Catherine Adhiambo Mwangale;

3. Prohibiting Coastal Drugs, LLC, from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until it is reinstated if it is revoked;

4. Prohibiting Catherine Adhiambo Mwangale from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if

Pharmacy Permit Number PHY 55429 is placed on probation or until it is reinstated if it is revoked;

5. Prohibiting Hema M. Patel from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until it is reinstated if it is revoked;

6. Prohibiting Alpesh M. Patel from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55429 is placed on probation or until it is reinstated if it is revoked;

7. Prohibiting Catherine Adhiambo Mwangale from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License number RPH 44540 is placed on probation or until it is reinstated if it is revoked;

8. Ordering Coastal Drugs, LLC, and Catherine Adhiambo Mwangale, jointly and severally, to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and,

9. Taking such other and further action as deemed necessary and proper.

DATED: 9/7/2023

Sodergren,
Anne@DCA

Digitally signed by Sodergren,
Anne@DCA
Date: 2023.09.07 20:03:37
-07'00'

ANNE SODERGREN
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

LA2023601260
66103594.docx